Abaloparatide has selective activation of the PTH1R and has been described as having an advantage over teriparatide in that it does not activate osteoclasts to the same extent.81 In human studies for postmenopausal osteoporosis with fracture risk as an outcome, abaloparatide significantly reduced fracture risk and increased trabecular bone scores.10, 82, 83 Very few studies have been performed to evaluate the effect of abaloparatide on fracture healing. Here, PTH1R is linked to postmenopausal osteoporosis.